1
|
Wu J, Liu J, Qu C, Wang Y, Zhu Y, Zhang Y, Li H, Zhang B, Sun Y, Zou W. Study of immune responses in mice to oral administration of Flor·Essence. Mol Clin Oncol 2020; 12:533-540. [PMID: 32337035 DOI: 10.3892/mco.2020.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Accepted: 11/18/2019] [Indexed: 11/06/2022] Open
Abstract
Flor·Essence (FE), a natural food grade herbal formula product manufactured by Flora Manufacturing & Distributing Ltd., has been used by patients with cancer in North America to stimulate immune cells in order to attenuate or reverse immune damage. To elucidate the mechanisms underlying the effects of FE on the immune system, spleen lymphocyte proliferation was analyzed by an MTT assay, and the phagocytic capacity of macrophages was measured via the neutral red phagocytosis method. The cytotoxicity of natural killer (NK) cells towards K562 cells was assessed via a CytoTox 96 assay. The production of the cytokines interleukin (IL)-12 and interferon (IFN)-γ in the peripheral blood was determined via ELISA and PCR analysis. The expression levels of caveolin-1 and NF-κB were measured via western blotting. In addition, cyclophosphamide was used to establish a mouse model of immunosuppression. It was found that the proliferation of splenocytes, the phagocytic capacity of macrophages and the cytotoxicity of NK cells against K562 cells were increased after oral administration of FE to mice. FE augmented the production of IL-12 and IFN-γ in the peripheral blood of mice. FE significantly increased the expression of proliferating cell nuclear antigen and caveolin-1, and decreased NF-κB expression. Finally, FE enhanced the viability of immune cells from cyclophosphamide-treated immunosuppressed mice. The results indicated that FE could activate immune responses and enhance natural immunity, suggesting that oral administration of FE can activate the body's immune response and resist damage caused by cyclophosphamide chemotherapy.
Collapse
Affiliation(s)
- Jingxin Wu
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China
| | - Jia Liu
- School of Life Science and Biotechnology, Faculty of Chemical, Environmental and Biological Science and Technology, Dalian University of Technology, Dalian, Liaoning 116024, P.R. China
| | - Chao Qu
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China.,Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, Dalian, Liaoning 116029, P.R. China
| | - Yuxin Wang
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China
| | - Yan Zhu
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China
| | - Yejun Zhang
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China.,Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, Dalian, Liaoning 116029, P.R. China
| | - Hongyan Li
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China.,Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, Dalian, Liaoning 116029, P.R. China
| | - Bingqiang Zhang
- Qingdao Ruiside Biotechnology Co., Ltd., Qingdao, Shandong 266111, P.R. China
| | - Yaru Sun
- Qingdao Ruiside Biotechnology Co., Ltd., Qingdao, Shandong 266111, P.R. China
| | - Wei Zou
- College of Life Science, Liaoning Normal University, Dalian, Liaoning 116081, P.R. China.,Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, Dalian, Liaoning 116029, P.R. China
| |
Collapse
|
2
|
Precision medicine: integration of genetics and functional genomics in prediction of bronchiolitis obliterans after lung transplantation. Curr Opin Pulm Med 2019; 25:308-316. [PMID: 30883449 DOI: 10.1097/mcp.0000000000000579] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW Lung transplantation (LTx) can be a life saving treatment in end-stage pulmonary diseases, but survival after transplantation is still limited. Posttransplant development of chronic lung allograft dysfunction with bronchiolits obliterans syndrome (BOS) as the major subphenotype, is the main cause of morbidity and mortality. Early identification of high-risk patients for BOS is a large unmet clinical need. In this review, we discuss gene polymorphisms and gene expression related to the development of BOS. RECENT FINDINGS Candidate gene studies showed that donor and recipient gene polymorphisms affect transplant outcome and BOS-free survival after LTx. Both selective and nonselective gene expression studies revealed differentially expressed fibrosis and apoptosis-related genes in BOS compared with non-BOS patients. Significantly, recent microarray expression analysis of blood and broncho-alveolar lavage suggest a role for B-cell and T-cell responses prior to the development of BOS. Furthermore, 6 months prior to the development of BOS differentially expressed genes were identified in peripheral blood cells. SUMMARY Genetic polymorphisms and gene expression changes are associated with the development of BOS. Future genome wide studies are needed to identify easily accessible biomarkers for prediction of BOS toward precision medicine.
Collapse
|
3
|
Wang X, Fu JH, Xue XD. Expression dynamics of caveolin-1 in fibroblasts of newborn rats with chronic lung disease and its impact on lung fibroblast proliferation. Acta Cir Bras 2017; 32:359-368. [PMID: 28591365 DOI: 10.1590/s0102-865020170050000005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2017] [Accepted: 04/19/2017] [Indexed: 11/21/2022] Open
Abstract
Purpose: To evaluate the changes of caveolin-1 in lung fibroblasts in newborn Wistar rats when exposed to hyperoxic conditions, as well as lung fibroblasts cell cycle. Methods: One hundred newborn Wistar rats were randomly divided (50 rats/group) into experimental and control groups, exposed to hyperoxic conditions or normal air, respectively. The fraction of inspired oxygen (FiO2) in the experimental group was 90%, whereas this value was 21% in the control group. Lung fibroblasts were collected on days 3, 7, and 14 of the experiment. Caveolin-1 expression dynamics in lung fibroblasts was assayed in each group by immunofluorescence and Western blot analyses. Flow cytometry (FCM) was used to assess the proportions of lung fibroblasts at different stages of the cell cycle. Results: On day 3, no significant difference in caveolin-1 expression was observed between the hyperoxic and control groups; however, on days 7 and 14, caveolin-1 expression was significantly lower in the hyperoxic group than in the control (P<0.05). No apparent differences were observed in caveolin-1 expression in the control group at the different time points. Using FCM analysis, we showed that the proportion of lung fibroblasts in G0/G1 phase in the hyperoxic group decreased compared to that of the control group on day 7, while the proportion of S-phase cells increased (P<0.05). These differences were more significant when the groups were compared on day 14 (P<0.01). Conclusion: After seven days the exposure to hyperoxic conditions, lung fibroblasts proliferated and caveolin-1 expression decreased.
Collapse
Affiliation(s)
- Xin Wang
- MD, Department of Pediatrics, Shengjing Hospital, China Medical University, Shenyang, China. Conception and design of the study, technical procedures, acquisition and analysis of data, manuscript writing
| | - Jian-Hua Fu
- MD, Department of Pediatrics, Shengjing Hospital, China Medical University, Shenyang, China. Analysis and interpretation of data, manuscript writing
| | - Xin-Dong Xue
- Professor, Department of Pediatrics, Shengjing Hospital, China Medical University, Shenyang, China. Conception, design, intellectual and scientific content of the study; critical revision; final approval the manuscript
| |
Collapse
|
4
|
Simmonds MJ. Using Genetic Variation to Predict and Extend Long-term Kidney Transplant Function. Transplantation 2016; 99:2038-48. [PMID: 26262502 DOI: 10.1097/tp.0000000000000836] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Renal transplantation has transformed the life of patients with end-stage renal disease and other chronic kidney disorders by returning endogenous kidney function and enabling patients to cease dialysis. Several clinical indicators of graft outcome and long-term function have been established. Although rising creatinine levels and graft biopsy can be used to determine graft loss, identifying early predictors of graft function will not only improve our ability to predict long-term graft outcome but importantly provide a window of opportunity to therapeutically intervene to preserve graft function before graft failure has occurred. Since understanding the importance of matching genetic variation at the HLA region between donors and recipients and translating this into clinical practise to improve transplant outcome, much focus has been placed on trying to identify additional genetic predictors of transplant outcome/function. This review will focus on how candidate gene studies have identified variants within immunosuppression, immune response, fibrotic pathways, and specific ethnic groups, which correlate with graft outcome. We will also discuss the challenges faced by candidate gene studies, such as differences in donor and recipient selection criteria and use of small data sets, which have led to many genes failing to be consistently associated with transplant outcome. This review will also look at how recent advances in our understanding of and ability to screen the genome are starting to provide new insights into the mechanisms behind long-term graft loss and with it the opportunity to target these pathways therapeutically to ultimately increase graft lifespan and the associated benefits to patients.
Collapse
Affiliation(s)
- Matthew J Simmonds
- 1 Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital, Headington, Oxford, United Kingdom
| |
Collapse
|
5
|
Hamilton A, Mittal S, Barnardo MCNM, Fuggle SV, Friend P, Gough SCL, Simmonds MJ. Genetic variation in caveolin-1 correlates with long-term pancreas transplant function. Am J Transplant 2015; 15:1392-9. [PMID: 25787790 DOI: 10.1111/ajt.13104] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Revised: 11/11/2014] [Accepted: 11/11/2014] [Indexed: 01/25/2023]
Abstract
Pancreas transplantation is a successful treatment for a selected group of people with type 1 diabetes. Continued insulin production can decrease over time and identifying predictors of long-term graft function is key to improving survival. The aim of this study was to screen subjects for variation in the Caveolin-1 gene (Cav1), previously shown to correlate with long-term kidney transplant function. We genotyped 435 pancreas transplant donors and 431 recipients who had undergone pancreas transplantation at the Oxford Transplant Centre, UK, for all known common variation in Cav1. Death-censored cumulative events were analyzed using Kaplan-Meier and Cox regression. Unlike kidney transplantation, the rs4730751 variant in our pancreas donors or transplant recipients did not correlate with long-term graft function (p = 0.331-0.905). Presence of rs3801995 TT genotype (p = 0.009) and rs9920 CC/CT genotype (p = 0.010) in our donors did however correlate with reduced long-term graft survival. Multivariate Cox regression (adjusted for donor and recipient transplant factors) confirmed the association of rs3801995 (p = 0.009, HR = 1.83;[95% CI = 1.16-2.89]) and rs9920 (p = 0.037, HR = 1.63; [95% CI = 1.03-2.73]) with long-term graft function. This is the first study to provide evidence that donor Cav1 genotype correlates with long-term pancreas graft function. Screening Cav1 in other datasets is required to confirm these pilot results.
Collapse
Affiliation(s)
- A Hamilton
- Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Oxford, UK
| | | | | | | | | | | | | |
Collapse
|
6
|
Ruttens D, Vandermeulen E, Verleden SE, Bellon H, Vos R, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden GM. Role of genetics in lung transplant complications. Ann Med 2015; 47:106-15. [PMID: 25766881 DOI: 10.3109/07853890.2015.1004359] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
There is increasing knowledge that patients can be predisposed to a certain disease by genetic variations in their DNA. Extensive genetic variation has been described in molecules involved in short- and long-term complications after lung transplantation (LTx), such as primary graft dysfunction (PGD), acute rejection, respiratory infection, chronic lung allograft dysfunction (CLAD), and mortality. Several of these studies could not be confirmed or were not reproduced in other cohorts. However, large multicenter prospective studies need to be performed to define the real clinical consequence and significance of genotyping the donor and receptor of a LTx. The current review presents an overview of genetic polymorphisms (SNP) investigating an association with different complications after LTx. Finally, the major drawbacks, clinical relevance, and future perspectives will be discussed.
Collapse
Affiliation(s)
- D Ruttens
- KU Leuven, and UZ Leuven, Department of Clinical and Experimental Medicine, Laboratory of Pneumology, Lung Transplant Unit , Leuven , Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|